Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors (NCT05121545) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors
United States11 participantsStarted 2022-04-06
Plain-language summary
This is a single arm, phase I study, evaluating the feasibility, toxicity, and degree of tumor response after novel proton pencil beam scanning (PBS GRID) treatment in patients with bulky tumors that are difficult to manage.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age \> 18
* Histologically or cytologically confirmed invasive cancer
* Bulky tumor \> 7 cm, determined clinically and/or radiographically, at the time of evaluation prior to enrollment
* Treated indicated for palliative intent
* Eastern Cooperative Oncology Group (ECOG) performance status \< 2
* Anticipated treatment deemed safe on pre-review by PI
* For patients with prior Radiation Therapy (RT): Dicoms must be available for dose fusion if overlap anticipated with GRID
* Willing and able to provide informed consent
* Discussion with medical oncology or surgical specialty
Exclusion Criteria:
* Age \< 18
* ECOG performance status 3-4
* Planned for definitive, curative management
* For patients with prior RT that overlaps with Pro-GRID: Dicoms not available Pregnant women
* Tumor encasing critical structure, as defined by the treating MD.
What they're measuring
1
Feasibility of the Pro-GRID intervention as assessed by success of intervention delivery for a number of participants
Timeframe: 1.5 years
Trial details
NCT IDNCT05121545
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins